跳至主要内容
临床试验/CTRI/2020/12/030086
CTRI/2020/12/030086尚未招募2 期

Safety and Efficacy of Oral Nutritional Supplement (RenoDiet-HP) in Patients with Chronic Kidney Disease Undergoing Maintenance Haemodialysis - RenoDiet-HP in CKD

Pulse Pharmaceuticals Pvt Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
2 期
状态
尚未招募

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1. All consenting patients with CKD, above 18 years of age, and receiving twice or thrice weekly maintenance hemodialysis for atleast 6 months at the outpatient hemodialysis unit will be included in the study.
  • 2. Patients willing to sign the Informed Consent Form (ICF).

排除标准

  • 1. Patients with intercurrent acute illnesses.
  • 2. Bodyweight less than 40 kg.
  • 3. Documented history of dialysis non-compliance.
  • 4. Documented malabsorption syndrome.
  • 5. Contraindications to any ingredient of RenoDiet-HP.
  • 6. Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with trial conduct or completion. (Chronic illness may include but is not limited to, cardiac, renal, autoimmune, hepatic, haematological, genetic disorders, atopic conditions, congenital defects, diabetes, convulsions or encephalopathy, tuberculosis etc.).
  • 7. Pregnant & Lactating women.
  • 8. Patients who are not willing to sign the ICF.

研究者

相似试验